Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antigens Involved in Adaptive Immunity

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Virus-like and Virus Replicon Particles Targeting Multiple B-Cell Antigens Do Not Protect Against African Swine Fever Virus.

Vaccines·2026

Same author

γδ T cells at the interface of innate and adaptive immunity in cancer.

Journal for immunotherapy of cancer·2026

Same author

Targeted Lymph Node Immunization with Serotype-Specific Dengue VLP Vaccines Enhances Antibody Avidity and Specificity.

Vaccines·2025

Same author

Versatile and Scalable Nanoparticle Vaccine as a Scaffold Against Newly Emerging Influenza Viruses.

Viruses·2025

Same author

Pathogenic T Follicular Helper Cells in Bullous Pemphigoid: Lessons from a Murine Model.

The Journal of investigative dermatology·2025

Same author

The impact of viral evolution on vaccine development for SARS-CoV-2.

Current opinion in immunology·2025

Same journal

Decoding the "Metallic" Immune Imprint: Single-Cell Exposomics Reveals the Immune Imprint of Fire Smoke.

Allergy·2026

Same journal

Immunonutrition in Early Life: The Role of Complementary Feeding, Dietary Patterns, and Nutritional Exposures on the Health of Young Children-An EAACI Scoping Review.

Allergy·2026

Same journal

Detergent-Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans.

Allergy·2026

Same journal

Global Variation in Timing of Allergenic Food Introduction for Food Allergy Prevention: An International Survey of Healthcare Professionals.

Allergy·2026

Same journal

Deficiency of Mitochondrial Fatty Acid Enzyme, CPT1A, Underlies Airway Epithelial Barrier Dysfunction in Severe Asthma.

Allergy·2026

Same journal

Surgical Management of Non-Allergic Rhinitis-An EAACI Task Force Position Paper.

Allergy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 13, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

A Case for Anti-IgE Vaccination.

Paul Engeroff^1,2, Zahra Gharailoo^1,2, Monique Vogel^1,2

¹Department of BioMedical Research (DBMR), University of Bern, Bern, Switzerland.

|March 12, 2026

Summary

This summary is machine-generated.

Anti-IgE vaccination offers a safe and cost-effective alternative to omalizumab for treating IgE-mediated allergies. This approach neutralizes free Immunoglobulin E (IgE) without activating immune cells, providing long-term allergy control.

Keywords:

Antibodies CD23 FcεRI allergy asthma atopy basophils chronic rhinosinusitis food allergy mast cells omalizumab urticaria

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Related Experiment Videos

Last Updated: Mar 13, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Area of Science:

Immunology
Allergy Research
Vaccine Development

Background:

Immunoglobulin E (IgE) drives allergic reactions by binding to FcεRI on immune cells.
Current anti-IgE therapy (omalizumab) is effective but costly and requires repeated administration.
Developing safe and accessible long-term allergy treatments remains a significant challenge.

Purpose of the Study:

To review emerging concepts in IgE biology and therapeutic IgE neutralization.
To explore the potential of anti-IgE vaccination as a safe and cost-effective allergy treatment.
To evaluate the safety and efficacy of novel anti-IgE vaccination strategies.

Main Methods:

Review of current literature on IgE biology and therapeutic neutralization strategies.
Analysis of recent research on vaccine-induced anti-IgE antibodies.
Comparison of vaccine-induced antibody mechanisms with natural anti-IgE autoantibodies.

Main Results:

Vaccine-induced anti-IgE antibodies selectively neutralize free IgE, avoiding effector cell activation.
This mechanism mimics natural anti-IgE autoantibodies involved in IgE homeostasis.
Emerging data suggest anti-IgE vaccination is safe and biologically plausible.

Conclusions:

Anti-IgE vaccination represents a promising strategy for long-term control of IgE-mediated allergic diseases.
This approach offers a potentially more accessible and cost-effective alternative to current therapies.
Further development of anti-IgE vaccines is warranted based on safety and biological rationale.